Dupilumab, a monoclonal antibody targeting interleukin (IL)-4 and IL-13, has been approved for moderate to severe AD; however, its long-term effects remain uncertain, with reports of T helper (Th)1-mediated disorders, such as psoriasis [9]. This evidence concerns the gene IL13 and Alzheimer disease.